U.S. Markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,785.56
    +376.92 (+0.89%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease.

  • The 138-subject study met its primary endpoints and all key secondary endpoints at 24 weeks.

  • Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives for biologic-naïve patients, compared to those treated with antihistamines alone (placebo).

  • Sanofi and Regeneron are jointly developing Dupilumab under a global collaboration agreement.

  • Data demonstrated a 63% reduction in itch severity with Dupixent vs. 35% with standard-of-care. 65% reduction in urticaria activity (itch and hives) severity with Dupixent vs. 37% with standard-of-care was observed.

  • For the 24-week treatment period, the occurrence of treatment-emergent adverse events was generally similar between the Dupixent and placebo groups (50% of Dupixent patients and 59% of placebo patients).

  • The most common adverse events were injection site reactions (11% Dupixent, 13% placebo).

  • Another trial will evaluate Dupixent in adults and adolescents who remain symptomatic despite standard-of-care treatment and are intolerant or incomplete responders to an anti-IgE therapeutic (omalizumab).

  • Data readout from the study is in H1 of 2022. Sanofi and Regeneron plan to begin submissions in 2022. In addition to CSU, Dupixent is being evaluated in chronic inducible urticaria triggered by cold in an ongoing Phase 3 trial.

  • Price Action: SNY shares are trading higher by 0.73% at $52.44, while REGN stock closed at $586.41 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.